ArticleACS nano2015
Characterizing the interactions of organic nanoparticles with renal epithelial cells in vivo.
Article in ACS nano, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 63 citations in OpenAlex.
- First-in-Human Study of the Carbohydrate NanoparticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- pH-Responsive Self-Assembly of Renal-Clearable Nanoparticles in the Kidneys: One Assembly per Endosome.Journal of the American Chemical Society · 2025Article
- Selenium Nanoparticles in Protecting the Brain from Stroke: Possible Signaling and Metabolic Mechanisms.Nanomaterials (Basel, Switzerland) · 2024Review
- Highly Active Myeloid Therapy for Cancer.ACS nano · 2023Article
- Targeted nanotherapy for kidney diseases: a comprehensive review.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Review
- Nanotechnology in Stroke: New Trails with Smaller Scales.Biomedicines · 2023Review
- Advanced Drug Delivery Systems for Renal Disorders.Gels (Basel, Switzerland) · 2023Review
- Novel Drug Delivery Technologies and Targets for Renal Disease.Hypertension (Dallas, Tex. : 1979) · 2022Review
- Deciphering albumin-directed drug delivery by imaging.Advanced drug delivery reviews · 2022Review
- Design, Development, Physicochemical Characterization, and In Vitro Drug Release of Formoterol PEGylated PLGA Polymeric Nanoparticles.Pharmaceutics · 2022Article
- Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro-In Vivo Correlation.Nanomaterials (Basel, Switzerland) · 2022Article
- Formoterol PLGA-PEG Nanoparticles Induce Mitochondrial Biogenesis in Renal Proximal Tubules.The AAPS journal · 2021Article
- Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases.Frontiers in genetics · 2021Review
- A review of the application of nanoparticles in the diagnosis and treatment of chronic kidney disease.Bioactive materials · 2020Review
- Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art.Pharmaceutics · 2020Review
- The archaeal Dps nanocage targets kidney proximal tubules via glomerular filtration.The Journal of clinical investigation · 2019Article
- Sex-dependent differences in water homeostasis in wild-type and V-ATPase B1-subunit deficient mice.PloS one · 2019Article
- Selective Nanoparticle Targeting of the Renal Tubules.Hypertension (Dallas, Tex. : 1979) · 2018Article
- In Vivo X-ray Imaging of Transport of Renal Clearable Gold Nanoparticles in the Kidneys.Angewandte Chemie (International ed. in English) · 2017Article
- Polymer Nanoparticle Engineering for Podocyte Repair: From in Vitro Models to New Nanotherapeutics in Kidney Diseases.ACS omega · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Nanotechnology approaches are actively being pursued for drug delivery, novel diagnostics, implantable devices, and consumer products. While considerable research has been performed on the effects of these materials on targeted tumor or phagocytic cells, relatively little is known about their effects on renal cells. This becomes critical for supersmall nanoparticles (<10 nm), designed to be renally excreted. The active endocytic machinery of kidney proximal tubules avidly internalizes filtered proteins, which may also be the case for filtered nanoparticles. To test whether such interactions affect kidney function, we injected mice with either 5 nm dextran-based nanoparticles (DNP) that are similar in composition to FDA-approved materials or poly(amido amine) dendrimer nanoparticles (PNP) of comparable size. These fluorescently tagged nanoparticles were both filtered and internalized by renal tubular epithelial cells in a dose- and time-dependent fashion. The biological effects were quantitated by immunocytochemistry, measuring kidney injury markers and performing functional tests. DNP administration resulted in a dose-dependent increase in urinary output, while cellular albumin endocytosis was increased. The expression of megalin, a receptor involved in albumin uptake, was also increased, but AQP1 expression was unaffected. The effects after PNP administration were similar but additionally resulted in increased clathrin expression and increased endocytosis of dextran. We conclude that there are no major detrimental renal effects of DNP on overall kidney function, but changes in endocytosis-mediating protein expression do occur. These studies provide a framework for the testing of additional nanoparticle preparations as they become available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.